Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas C Turner

Showing results (41-50 of 138) with videos related to

Pageof 14
Sort By:
The EMBO Journal|April 5, 2008
A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitorNicholas C Turner, Christopher J Lord, Elizabeth Iorns, et al.
Breast Cancer Research : BCR|July 2, 2014
Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibitionElena López-Knowles, Corrinne V Segal, Qiong Gao, et al.
Cancers|August 29, 2024
The Clinical Features and Outcomes of Pseudocirrhosis in Breast CancerEdward Phillips, Mantegh Sethi, Surammiya Vasanthakumar, et al.
Cancer Discovery|May 26, 2012
Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1Marieke Aarts, Rachel Sharpe, Isaac Garcia-Murillas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2013
Noninvasive detection of HER2 amplification with plasma DNA digital PCRHeidrun Gevensleben, Isaac Garcia-Murillas, Monika K Graeser, et al.
Scientific Reports|October 14, 2020
PIK3CA mutation enrichment and quantitation from blood and tissueIeva Keraite, Virginia Alvarez-Garcia, Isaac Garcia-Murillas, et al.
Trials|May 7, 2022
Operational complexity versus design efficiency: challenges of implementing a phase IIa multiple parallel cohort targeted treatment platform trial in advanced breast cancerClaire Snowdon, Sarah Kernaghan, Laura Moretti, et al.
Cancer Cell|February 5, 2008
Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancerElizabeth Iorns, Nicholas C Turner, Richard Elliott, et al.
Breast Cancer Research and Treatment|February 4, 2022
Clinical outcomes in patients with triple negative or HER2 positive lobular breast cancer: a single institution experienceAlicia Okines, Tazia Irfan, Bernice Asare, et al.
Nature Communications|November 17, 2023
Genomic profiling and pre-clinical modelling of breast cancer leptomeningeal metastasis reveals acquisition of a lobular-like phenotypeAmanda Fitzpatrick, Marjan Iravani, Adam Mills, et al.
Pageof 14

Showing results (41-50 of 138) with videos related to

Sort By:
Pageof 14
The EMBO Journal|April 5, 2008
A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitorNicholas C Turner, Christopher J Lord, Elizabeth Iorns, et al.
Breast Cancer Research : BCR|July 2, 2014
Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibitionElena López-Knowles, Corrinne V Segal, Qiong Gao, et al.
Cancers|August 29, 2024
The Clinical Features and Outcomes of Pseudocirrhosis in Breast CancerEdward Phillips, Mantegh Sethi, Surammiya Vasanthakumar, et al.
Cancer Discovery|May 26, 2012
Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1Marieke Aarts, Rachel Sharpe, Isaac Garcia-Murillas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2013
Noninvasive detection of HER2 amplification with plasma DNA digital PCRHeidrun Gevensleben, Isaac Garcia-Murillas, Monika K Graeser, et al.
Scientific Reports|October 14, 2020
PIK3CA mutation enrichment and quantitation from blood and tissueIeva Keraite, Virginia Alvarez-Garcia, Isaac Garcia-Murillas, et al.
Trials|May 7, 2022
Operational complexity versus design efficiency: challenges of implementing a phase IIa multiple parallel cohort targeted treatment platform trial in advanced breast cancerClaire Snowdon, Sarah Kernaghan, Laura Moretti, et al.
Cancer Cell|February 5, 2008
Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancerElizabeth Iorns, Nicholas C Turner, Richard Elliott, et al.
Breast Cancer Research and Treatment|February 4, 2022
Clinical outcomes in patients with triple negative or HER2 positive lobular breast cancer: a single institution experienceAlicia Okines, Tazia Irfan, Bernice Asare, et al.
Nature Communications|November 17, 2023
Genomic profiling and pre-clinical modelling of breast cancer leptomeningeal metastasis reveals acquisition of a lobular-like phenotypeAmanda Fitzpatrick, Marjan Iravani, Adam Mills, et al.
Pageof 14